STAAR Surgical (NASDAQ:STAA - Get Free Report) was downgraded by equities researchers at Zacks Research from a "strong-buy" rating to a "hold" rating in a research report issued on Tuesday, Zacks reports.
A number of other brokerages have also commented on STAA. UBS Group set a $34.00 price target on STAAR Surgical in a report on Thursday, November 5th. William Blair set a $33.00 price objective on shares of STAAR Surgical in a report on Thursday, August 13th. Jefferies Financial Group decreased their target price on shares of STAAR Surgical from $28.00 to $23.00 and set a "buy" rating for the company in a research report on Tuesday, September 22nd. Stifel Nicolaus raised shares of STAAR Surgical from a "hold" rating to a "buy" rating and raised their target price for the company from $28.00 to $31.00 in a research note on Tuesday, September 29th. Finally, Wedbush dropped their price target on shares of STAAR Surgical from $40.00 to $37.00 and set an "outperform" rating on the stock in a research report on Thursday, August 13th. Four research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have issued a Sell rating to the company. According to MarketBeat, STAAR Surgical presently has an average rating of "Hold" and a consensus price target of $29.00.
Read Our Latest Research Report on STAA
STAAR Surgical Trading Down 0.8%
Shares of NASDAQ STAA opened at $25.35 on Tuesday. STAAR Surgical has a 12-month low of $15.59 and a 12-month high of $35.87. The company has a market cap of $1.27 billion, a PE ratio of -2,535,000.00 and a beta of 1.22. The stock has a 50 day simple moving average of $23.09 and a 200-day simple moving average of $23.91.
STAAR Surgical (NASDAQ:STAA - Get Free Report) last posted its earnings results on Wednesday, November 4th. The medical instruments supplier reported $0.11 EPS for the quarter, beating the consensus estimate of $0.05 by $0.06. STAAR Surgical had a return on equity of 8.43% and a net margin of 0.16%. The firm had revenue of $83.41 million for the quarter, compared to analysts' expectations of $78.73 million. During the same period last year, the firm earned $0.08 EPS. The firm's revenue was down 11.9% compared to the same quarter last year. Sell-side analysts forecast that STAAR Surgical will post 0.43 earnings per share for the current fiscal year.
STAAR Surgical announced that its Board of Directors has authorized a stock buyback plan on Thursday, September 24th that permits the company to repurchase $50 million in outstanding shares. This repurchase authorization permits the medical instruments supplier to reacquire up to 5.2% of its shares through open market purchases. Stock repurchase plans are typically an indication that the company's management believes its shares are undervalued.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of the company. Zacks Investment Management raised its position in STAAR Surgical by 8.8% in the third quarter. Zacks Investment Management now owns 90,165 shares of the medical instruments supplier's stock worth $2,039,000 after acquiring an additional 7,291 shares in the last quarter. Algert Global LLC bought a new position in shares of STAAR Surgical during the 3rd quarter valued at about $24,683,000. State of Tennessee Department of Treasury boosted its position in shares of STAAR Surgical by 10.8% during the 3rd quarter. State of Tennessee Department of Treasury now owns 16,384 shares of the medical instruments supplier's stock valued at $370,000 after purchasing an additional 1,595 shares in the last quarter. Jump Financial LLC acquired a new position in shares of STAAR Surgical in the 3rd quarter worth approximately $380,000. Finally, EP Wealth Advisors LLC acquired a new position in shares of STAAR Surgical in the 3rd quarter worth approximately $473,000. 96.70% of the stock is owned by institutional investors and hedge funds.
STAAR Surgical Company Profile
(
Get Free Report)
STAAR Surgical is a medical device company focused on ophthalmic surgery and vision correction. The company develops, manufactures and markets implantable lenses and related products designed to reduce or eliminate dependence on glasses or contact lenses. Its principal product line is the EVO Visian Implantable Collamer Lens (ICL), a lens implanted inside the eye to correct myopia, with or without astigmatism. Unlike procedures that remove corneal tissue, ICL surgery preserves the eye's natural lens and is designed to be removable.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider STAAR Surgical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and STAAR Surgical wasn't on the list.
While STAAR Surgical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.